5. Segment information
Geographical information
In 2021 our continuing operations were mainly located in Belgium, France, the Netherlands, Germany, Italy, Spain, Switzerland and the United Kingdom and the revenues from our collaboration partner Gilead represented almost 100% of the collaboration revenues.
Following table summarizes our collaboration revenues by destination of customer:
|
Year ended 31 December, |
|
|---|---|---|
(thousands of €) |
2021 |
2020 |
United States of America |
467,978 |
472,445 |
Europe |
2,114 |
5,605 |
Total collaboration revenues |
470,093 |
478,051 |
Following table summarizes our collaboration revenues by major customers:
|
Year ended 31 December, |
|||
|---|---|---|---|---|
|
2021 |
2020 |
||
|
(thousands of €) |
% |
(thousands of €) |
% |
Gilead |
|
|
|
|
United States of America |
467,978 |
100% |
472,445 |
99% |
Europe |
2,071 |
0% |
1,460 |
0% |
Novartis |
|
|
|
|
Europe |
- |
0% |
4,125 |
1% |
Total collaboration revenues from major customers |
470,049 |
100% |
478,030 |
100% |
On 31 December 2021, we held €198 million (€171 million in 2020) of property, plant and equipment and intangible assets distributed as follows:
|
31 December |
|
|---|---|---|
(thousands of €) |
2021 |
2020 |
Belgium |
98,295 |
113,524 |
France |
21,051 |
18,398 |
The Netherlands |
66,621 |
28,210 |
Switzerland |
7,181 |
7,668 |
Spain |
3,029 |
2,755 |
Other |
1,438 |
388 |
Total |
197,615 |
170,943 |